CAPTURE Data Post Hoc Analysis: Cardiovascular Disease by CKD Risk Group

The multinational, cross-sectional, noninterventional CAPTURE study was designed to examine the 2019 prevalence of cardiovascular disease in patients with type 2 diabetes across 13 countries. Giuseppina Russo, MD, PhD, and colleagues conducted a post hoc analysis of data from CAPTURE to estimate the occurrence of cardiovascular disease and medication use among chronic kidney disease (CKD) risk groups.

Results of the analysis were reported during a virtual poster session at ASN Kidney Week 2020. The poster was titled Cardiovascular Disease and Medication Use by CKD Risk Groups in People with Type 2 Diabetes: A Post Hoc Analysis from CAPTURE.

CAPTURE was conducted between December 2018 and September 2019. Data on diagnoses of cardiovascular disease, estimated glomerular filtration rate (eGFR), urine albumin level, and use of glucose-lowering agents (GLA) and/or cardiovascular disease medications were collected during routine office visits. Patients were stratified by risk for CKD by eGFR and urine albumin threshold according to Kidney Disease Improving Global Outcomes (KDIGO) criteria.

The CAPTURE study included 9823 participants. Of those, 81% (n=7923) had eGFR data, 66% (n=6482) had data on urine creatinine ratio (UACR), and 59% (n=5829) had both measurements available. Stratification by eGFR was: >89 mL/min/1.72 m2, 35%; 60 to 89 mL/min/1.73 m2, 44%; 30 to 59 mL/min/1.73 m2, 18%; and <30 mL/min/1.73 m2, 3%. Stratification by UACR was <30 mg/g, 67%; 30 to 300 mg/g, 25%; and >300 mg/g, 8%.

By KDIGO risk for CKD, the prevalence of CKD was as follows: low risk, 29%; moderate risk, 44%; high risk, 53%; and very high risk, 59%. Use of GLAs decreased with increasing CKD, with the exception of insulin, which increased. Across the risk groups, the use of renin angiotensin aldosterone system inhibitors was 49% to 72%.

In conclusion, the researchers said, “The post hoc CAPTURE analysis demonstrated a positive association between cardiovascular disease prevalence and CKD risk. Cardiovascular medications with proven cardiovascular benefits, including GLA, were underused.”

Source: Russo G, Alguwaihes A, Bayram F, et al. Cardiovascular disease and medication use by CKD risk groups in people with type 2 diabetes: A post hoc analysis from CAPTURE. Abstract of a poster presented at the American Society of Nephrology virtual Kidney Week 2020 (PO0974), October 22, 2020. Funding for this poster was supplied by Novo Nordisk.